HRP20220025T1 - Režim doziranja valbenazina za liječenje hiperkinetičkih poremećaja kretanja - Google Patents

Režim doziranja valbenazina za liječenje hiperkinetičkih poremećaja kretanja Download PDF

Info

Publication number
HRP20220025T1
HRP20220025T1 HRP20220025TT HRP20220025T HRP20220025T1 HR P20220025 T1 HRP20220025 T1 HR P20220025T1 HR P20220025T T HRP20220025T T HR P20220025TT HR P20220025 T HRP20220025 T HR P20220025T HR P20220025 T1 HRP20220025 T1 HR P20220025T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
use according
daily dose
treatment
hyperkinetic movement
Prior art date
Application number
HRP20220025TT
Other languages
English (en)
Inventor
Christopher F. O'Brien
Original Assignee
Neurocrine Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences, Inc. filed Critical Neurocrine Biosciences, Inc.
Publication of HRP20220025T1 publication Critical patent/HRP20220025T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Claims (7)

1. Farmaceutski pripravak, naznačen time, da je za uporabu u postupku liječenja hiperkinetičkog poremećaja kretanja kod ljudskog pojedinca kojemu je to potrebno, pri čemu navedeni postupak obuhvaća davanje inhibitora VMAT2 (S)-2-amino-3-metil-butanska kiselina-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-1,3,4,6,7,11b-heksahidro-2H-pirido[2,1-a]izokinolin-2-ilester, ili njegove farmaceutski prihvatljive soli, ljudskom pojedincu u dnevnoj dozi od 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg ili 70 mg.
2. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da dnevna doza iznosi 40 mg.
3. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da dnevna doza iznosi 50 mg.
4. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da dnevna doza iznosi 60 mg.
5. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da dnevna doza iznosi 70 mg.
6. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da hiperkinetički poremećaj kretanja jest tardivna diskinezija.
7. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da farmaceutski prihvatljiva sol je dihidrokloridna sol ili ditosilatna sol.
HRP20220025TT 2014-05-06 2015-05-06 Režim doziranja valbenazina za liječenje hiperkinetičkih poremećaja kretanja HRP20220025T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
EP15724438.5A EP3139925B1 (en) 2014-05-06 2015-05-06 Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Publications (1)

Publication Number Publication Date
HRP20220025T1 true HRP20220025T1 (hr) 2022-04-01

Family

ID=53264772

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220025TT HRP20220025T1 (hr) 2014-05-06 2015-05-06 Režim doziranja valbenazina za liječenje hiperkinetičkih poremećaja kretanja

Country Status (23)

Country Link
US (3) US20170071932A1 (hr)
EP (2) EP3139925B1 (hr)
JP (3) JP6635945B2 (hr)
KR (4) KR20200133003A (hr)
CN (3) CN112741836A (hr)
AU (1) AU2015256012B2 (hr)
CA (1) CA2947736C (hr)
CY (1) CY1125058T1 (hr)
DK (2) DK3936130T3 (hr)
ES (1) ES2904526T3 (hr)
FI (1) FI3936130T3 (hr)
HR (1) HRP20220025T1 (hr)
HU (1) HUE057839T2 (hr)
IL (1) IL248745B (hr)
LT (2) LT3139925T (hr)
MX (1) MX2016014429A (hr)
NZ (1) NZ725826A (hr)
PL (1) PL3139925T3 (hr)
PT (2) PT3139925T (hr)
RS (2) RS62782B1 (hr)
RU (1) RU2753740C2 (hr)
SI (1) SI3139925T1 (hr)
WO (1) WO2015171802A1 (hr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10065952B2 (en) 2015-10-30 2018-09-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
JP6869988B2 (ja) 2015-12-23 2021-05-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
EP3473623B1 (en) * 2016-06-29 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of nbi-98854, preparation method therefor and use thereof
TW201827051A (zh) * 2016-12-02 2018-08-01 美商神經性分泌生物科學公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
US10703750B2 (en) 2017-01-10 2020-07-07 Sandoz Ag Crystalline valbenazine free base
CA3051829A1 (en) 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
US10954235B2 (en) 2017-02-27 2021-03-23 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
AU2018242134B2 (en) * 2017-04-01 2023-09-28 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
WO2018178243A2 (en) * 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JP7250006B2 (ja) 2017-09-21 2023-03-31 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 高投与量バルベナジン製剤ならびにそれに関連する組成物、方法およびキット
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
KR20200066661A (ko) 2017-10-10 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
RU2020114598A (ru) * 2017-11-08 2021-12-09 Фореси Фармасьютикалс Ко., Лтд. Сложные эфиры дигидротетрабеназина
JP7212958B2 (ja) 2017-12-26 2023-01-26 ▲蘇▼州科睿思制▲葯▼有限公司 バルベナジントシル酸塩の結晶形及びその製造方法並びに用途
AU2019261403A1 (en) 2018-04-25 2020-11-12 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
EP3806856A1 (en) 2018-06-14 2021-04-21 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
BR112021000019A2 (pt) 2018-08-15 2021-04-06 Neurocrine Biosciences Inc. Métodos para administração de certos inibidores de vmat2
WO2020070236A1 (en) 2018-10-04 2020-04-09 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
KR20220007105A (ko) * 2019-05-09 2022-01-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039627B2 (en) * 2006-11-08 2011-10-18 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
JP2010509336A (ja) * 2006-11-09 2010-03-25 ニューヨーク ユニバーシティ サンドイッチ材料の製造方法、ガラス／セラミック／ガラス複合構造物、ガラス／セラミック／ガラス、医科あるいは歯科補綴、およびガラス／ジルコニア／ガラスサンドイッチ材料
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
WO2011019956A2 (en) 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
AU2009303758B8 (en) 2008-09-18 2015-02-19 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CN103003275A (zh) * 2010-06-01 2013-03-27 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂
AU2013318182C1 (en) 2012-09-18 2022-01-20 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2015213778B2 (en) * 2014-02-07 2020-04-23 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof

Also Published As

Publication number Publication date
PT3936130T (pt) 2024-04-17
JP6635945B2 (ja) 2020-01-29
RU2016147523A (ru) 2018-06-08
US20200101063A1 (en) 2020-04-02
IL248745B (en) 2022-07-01
JP2021191799A (ja) 2021-12-16
NZ725826A (en) 2023-05-26
US20210196702A1 (en) 2021-07-01
KR20240011255A (ko) 2024-01-25
EP3139925B1 (en) 2021-12-01
KR20200133003A (ko) 2020-11-25
JP2017514850A (ja) 2017-06-08
MX2016014429A (es) 2017-04-06
KR20220140647A (ko) 2022-10-18
CA2947736C (en) 2023-04-18
CN106456629A (zh) 2017-02-22
RU2016147523A3 (hr) 2018-12-28
EP3936130B1 (en) 2024-02-14
LT3139925T (lt) 2022-01-25
DK3936130T3 (da) 2024-03-25
CN112741835A (zh) 2021-05-04
DK3139925T3 (da) 2021-12-20
WO2015171802A1 (en) 2015-11-12
CN112741836A (zh) 2021-05-04
FI3936130T3 (fi) 2024-04-23
PL3139925T3 (pl) 2022-03-21
PT3139925T (pt) 2022-01-26
CY1125058T1 (el) 2023-06-09
RS65359B1 (sr) 2024-04-30
EP3139925A1 (en) 2017-03-15
US20170071932A1 (en) 2017-03-16
CA2947736A1 (en) 2015-11-12
AU2015256012A1 (en) 2016-11-24
AU2015256012B2 (en) 2020-07-23
EP3936130A1 (en) 2022-01-12
ES2904526T3 (es) 2022-04-05
HUE057839T2 (hu) 2022-06-28
SI3139925T1 (sl) 2022-04-29
IL248745A0 (en) 2017-01-31
LT3936130T (lt) 2024-04-25
RU2753740C2 (ru) 2021-08-23
JP2019218407A (ja) 2019-12-26
RS62782B1 (sr) 2022-01-31
KR20160147044A (ko) 2016-12-21

Similar Documents

Publication Publication Date Title
HRP20220025T1 (hr) Režim doziranja valbenazina za liječenje hiperkinetičkih poremećaja kretanja
HRP20191957T1 (hr) Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba
HRP20201949T1 (hr) 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji
HRP20190764T1 (hr) Heterocikli sposobni modulirati odgovore t-stanica, i postupci za njihovu upotrebu
HRP20210529T1 (hr) Inhibitori za mk2 i njihove uporabe
IL257481B (en) Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof
HRP20211543T1 (hr) Derivati kinazolina koji se koriste za liječenje hiv-a
MA52257A (fr) Compositions pharmaceutiques comprenant blautia et leur administration orale
TN2018000121A1 (en) Valbenazine salts and polymorphs thereof
WO2016210180A3 (en) Vmat2 inhibitors for treating neurological diseases or disorders
BR112015008365A2 (pt) composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
JP2017514871A5 (hr)
JP2016501828A5 (hr)
JP2012180381A5 (hr)
EP4233846A3 (en) Pharmaceutical formulations
EA201792591A1 (ru) Фармацевтические препараты
EP3400964A4 (en) TASTE-MASKED AND ORAL ADMINISTRATIVE PHARMACEUTICAL PREPARATION WITH VARENICLIN OR PHARMACEUTICAL SALT OF IT
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
IL282163A (en) A pharmaceutical preparation for oral administration containing an aminopyrimidine derivative or its salt
HRP20240309T1 (hr) Kombinirani antibakterijski pripravak i kratkotrajni antibakterijski režim, koji uključuje linezolid, bedakvilin i pretomanid
SMT201600460B (it) Composizione farmaceutica per uso nel trattamento o prevenzione delle carenze di vitamine e minerali in pazienti che sono stati sottoposti a chirurgia di bypass gastrico
HK1214600A1 (zh) 種含磷吡啶並 嘧啶- -酮類化合物或其藥學上可接受的鹽、藥物組合物及其應用
BR112016005361A8 (pt) inibidores de girase tricíclica, composição, forma de dosagem, embalagem e dispositivo dispensador que os compreende, bem como uso dos mesmos
HK1243327A1 (zh) 包含螺旋藻和棕櫚酰基乙醇酰胺和/或其鹽或藥用上可接受衍生物的組合及其製劑，用於預防和/或治療過度活化的組織病症
GB201910294D0 (en) Liquid pharmaceutical composition for oral administration comprising paracetamol and codeine phosphate